Business News›Markets›Stocks›Live Blog› Q3 Results Today Live Updates: Adani Green Q3 PAT jumps 85% YoY to Rs 474 cr; HPCL Q3 PAT skyrockets 257% to Rs 2,544 cr
LIVE BLOG
Q3 Results Today Live Updates: Adani Green Q3 PAT jumps 85% YoY to Rs 474 cr; HPCL Q3 PAT skyrockets 257% to Rs 2,544 cr
23 Jan 2025 | 08:54:30 PM IST
59 companies to announce Q3 earnings today
Synopsis
Q3 Results 2025 Live Updates: The third-quarter earnings season is in full swing, with around 59 companies set to release their results on Thursday. Notable reports to keep an eye on include Ultratech Cement, Adani Green, Dr. Reddys, Mankind Pharma, and HPCL.
Q3 Results 2025 Live:
Show more- Adani Green Energy on Thursday reported a 85% year-on-year jump in its December quarter consolidated net profit at Rs 474 crore versus Rs 256 crore posted in the year ago period.
- Hindustan Petroleum Corporation (HPCL) on Thursday reported a 257% year-on-year growth in its December quarter consolidated net profit at Rs 2,544 crore versus Rs 713 crore posted in the year ago period.
- Dr Reddy's Laboratories on Thursday reported a 2% year-on-year growth in its December quarter consolidated net profit at Rs 1,413 crore versus Rs 1,379 crore posted in the year ago period. The Q3FY25 revenue from operations stood at Rs 8,359 crore which was up by 16% over Rs 7215 in the corresponding quarter of the previous financial year.
- Ultratech Cement reported a 17% year-on-year (YoY) decline in net profit, which stood at Rs 1,469.50 crore (attributable to shareholders), while revenue from operations increased by a modest 3% YoY to Rs 17,193 crore.
- ZEE Entertainment Enterprises (ZEEL) reported a 180% year-on-year (YoY) increase in its consolidated net profit, reaching Rs 164 crore in the third quarter. However, its operating revenue fell by 3% YoY to Rs 1,979 crore.
- Adani Energy Solutions reported a 73% year-on-year growth in its consolidated net profit for the December quarter, reaching Rs 562 crore, compared to Rs 325 crore in the same period last year.
1 New Update
Suryoday Small Finance Bank Q3 Results: Profit slumps 42% to Rs 33 crore
Suryoday Small Finance Bank on Thursday reported a 42% year-on-year fall in net profit for the third quarter, owing to higher operating and other expenses while its asset quality worsened.
The net profit stood at Rs 33.3 crore against Rs 57.2 crore in the year ago period. Pre-provision operating profit was 37.5% lower at Rs 71.4 crore against Rs 114.2 crore.
Net interest income rose by 9.2% to Rs 268.3 crore from Rs 245.7 crore. Total income increased by 3.4% at Rs 307.8 crore, while a 31% higher expenditure at Rs 456 crore pulled down profitability.
The net profit stood at Rs 33.3 crore against Rs 57.2 crore in the year ago period. Pre-provision operating profit was 37.5% lower at Rs 71.4 crore against Rs 114.2 crore.
Net interest income rose by 9.2% to Rs 268.3 crore from Rs 245.7 crore. Total income increased by 3.4% at Rs 307.8 crore, while a 31% higher expenditure at Rs 456 crore pulled down profitability.
Indus Towers Q3 Results: Profit at Rs 4,003 crore, Revenue from operations at 7,547 crore
Indus Towers Q3 Results:
Profit at Rs 4,003 crore
Revenue from operations at 7,547 crore
Profit at Rs 4,003 crore
Revenue from operations at 7,547 crore
United Spirits Q3 Results: Profit at Rs 473 crore, Revenue at Rs 7,731 crore
United Spirits Q3 Results:
Profit - Rs 473 crore
Revenue from operations: Rs 7,731 crore
Profit - Rs 473 crore
Revenue from operations: Rs 7,731 crore
Mankind Pharma Q3 Results: Profit falls 16% to Rs 384 crore
Mankind Pharma on Thursday said its consolidated net profit declined 16.5 per cent to Rs 384 crore in the third quarter ended December 31, 2024. The company had reported a net profit of Rs 460 crore for the October-December period of last fiscal.
Revenue from operations rose to Rs 3,230 crore from Rs 2,607 crore, Mankind Pharma said in a statement.
"We achieved a healthy revenue growth of 24 per cent YoY with strong adjusted EBITDA margin of 27.7 per cent in Q3FY25, driven by continued out performance in chronic, strong recovery in OTC and consolidation of BSV," Vice Chairman and MD Rajeev Juneja said.
Revenue from operations rose to Rs 3,230 crore from Rs 2,607 crore, Mankind Pharma said in a statement.
"We achieved a healthy revenue growth of 24 per cent YoY with strong adjusted EBITDA margin of 27.7 per cent in Q3FY25, driven by continued out performance in chronic, strong recovery in OTC and consolidation of BSV," Vice Chairman and MD Rajeev Juneja said.
Adani Green Q3 results live updates: Developing world's largest RE plant in Gujarat, says CEO Amit Singh
Adani Green CEO Amit Singh says: We are steadily developing the world’s largest RE plant in Khavda, Gujarat as well as large-scale plants in Rajasthan and other sites, supported by well aligned transmission planning. We have upgraded our supply chain to meet current and future regulatory compliances. Recently, we made significant progress in building the PPA pipeline by participating in various tenders
Adani Green Q3 results live updates: Power supply revenue at Rs 1,993 crore
Company's power supply revenue stood at Rs 1,993 crore in the reported quarter while that from the sale of goods/equipment and related services stood at Rs 293 crore.
Adani Green Q3 results live updates: Other revenue from ops at Rs 265 cr
The other revenue from operations stood at Rs 265 crore. This includes income from Viability Gap Funding and Change in Law, Income from Carbon Credit (net), Generation based incentive and Income from Project Management Consultancy services.
Adani Green Q3 results live updates: PAT down 8% on sequential basis
On a sequential basis, the profit after tax (PAT) was down by 8% versus Rs 515 crore reported in Q2FY25. Meanwhile, the topline fell 23% on a sequential basis versus Rs 3,055 crore reported in the July-September quarter of FY25.
Adani Green Q3 results: Cons PAT jumps 85% YoY to Rs 474 crore, revenue up 2%
Adani Green Energy on Thursday reported a 85% year-on-year jump in its December quarter consolidated net profit at Rs 474 crore versus Rs 256 crore posted in the year ago period. The revenue from operations in Q3FY25 stood at Rs 2,365 crore which was up by 2.3% over Rs 2,311 in the corresponding quarter of the previous financial year.
KFin Technologies Q3 Results: Profit rises 35% to Rs 90 crore
KFin Technologies Ltd on Thursday reported a 35 per cent year-on-year surge in profit after tax to Rs 90.18 crore for three months ended December 2024. The company had posted a profit after tax (PAT) of Rs 66.83 crore in the year-ago period, KFin Technologies said in a statement.
Revenue from operations stood at Rs 290 crore in the October-December quarter of the current financial year (FY25), a surge of 32.6 per cent from Rs 218.72 crore in the year-ago period.
Revenue from operations stood at Rs 290 crore in the October-December quarter of the current financial year (FY25), a surge of 32.6 per cent from Rs 218.72 crore in the year-ago period.
Cyient misses third-quarter profit estimates on higher costs
Indian engineering and technology firm Cyient reported a third-quarter profit below analysts' expectations on Thursday, hurt by slower growth in its biggest segment and higher costs.
Its profit declined to 1.22 billion rupees ($14.12 million) for the three months ended Dec. 31, from 1.47 billion rupees a year ago. Analysts had expected 1.71 billion rupees, according to data compiled by LSEG.
Its profit declined to 1.22 billion rupees ($14.12 million) for the three months ended Dec. 31, from 1.47 billion rupees a year ago. Analysts had expected 1.71 billion rupees, according to data compiled by LSEG.
HPCL Q3 Results Live Updates: HPCL average GRM down to $6 per barrel
The Average GRM during 3QFY25 was $6.01 per barrel down from $8.49 per barrel during 3QFY24.
HPCL Q3 Results Live Updates: Operational efficiencies behind stellar PAT growth
The company in its filing to the exchanges attributed it to robust physical performance and operational efficiencies in both refining and marketing divisions, coupled with improved margins.
HPCL Q3 Results Live Updates: QoQ PAT rise - 1,683%
On a quarter-on-quarter basis, the profit after tax (PAT) jumped by a staggering 1,683% versus Rs 143 crore reported in Q2FY25. Meanwhile, the revenue from the sale of products was up 10% against 1.07 lakh crore reported in Q2FY25.
Syngene net profit rose 18% in Q3FY25 to Rs 131 crore
Syngene International, the contract research and manufacturing services arm of Biocon reported 18% year-on-year (YoY) jump in net profit to Rs.131 crore in Q3FY25 led by growth across dedicated centres and development and manufacturing services, even as discovery services business remained soft.
The third quarter revenue from operations rose 11% YoY to Rs. 944 crore.
The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 16% YoY to Rs. 302 crore in Q3FY25. The EBITDA margin rose 190 basis points YoY to 31.4%.
The third quarter revenue from operations rose 11% YoY to Rs. 944 crore.
The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 16% YoY to Rs. 302 crore in Q3FY25. The EBITDA margin rose 190 basis points YoY to 31.4%.
HPCL Q3 Results: PAT at Rs 3,023 cr, Revenue at Rs 1.1 L cr
HPCL Q3 Results
PAT - Rs 3,023 cr
EBITDA Rs 5,970 cr
Revenue - Rs 1.1L cr
PAT - Rs 3,023 cr
EBITDA Rs 5,970 cr
Revenue - Rs 1.1L cr
Dr Reddys Lab Q3 results: Cons PAT jumps 2% YoY to Rs 1,413 crore, revenue up 16%
Dr Reddys Laboratories on Thursday reported a 2% year-on-year growth in its December quarter consolidated net profit at Rs 1,413 crore versus Rs 1,379 crore posted in the year ago period. Read More
Cyient Q3 Results: PAT - Rs 122.3 cr, Revenue - Rs 192.6 cr
Cyient Q3 Results:
PAT - Rs 122.3 cr vs Rs 147.2 cr YoY
Revenue - Rs 192.6 cr vs Rs 182.14 cr YoY
PAT - Rs 122.3 cr vs Rs 147.2 cr YoY
Revenue - Rs 192.6 cr vs Rs 182.14 cr YoY
Sona BLW Precision Forgings Q3 Results: Rs 1.6 per share dividend declared
Sona BLW Precision Forgings Q3 Results: Rs 1.6 per share dividend declared
Sona BLW Precision Forgings Q3 Results: PAT up at Rs 152 cr, revenue Rs 867 cr
Sona BLW Precision Forgings Q3 Results:
PAT - Rs 151.19 cr over Rs 132.70 cr YoY
Revenue - Rs 867.09 cr vs Rs 781.79 cr YoY
PAT - Rs 151.19 cr over Rs 132.70 cr YoY
Revenue - Rs 867.09 cr vs Rs 781.79 cr YoY
Q3 Results Today Live Updates | Adani Energy share price closes marginally higher post Q3 results
Price as on 03.58.00 PM, Click on company names for their live prices.
Q3 Results Today Live Updates | UltraTech Cement share price zooms 6.8% post Q3 results
Price as on 03.49.22 PM, Click on company names for their live prices.
Q3 Results Today Live Updates | Zee Ent's share price rises 3% post Q3 results
Shares of the company rose 2.88% to Rs 121 on BSE.
Q3 Results Today Live Updates | Adani Energy Q3 Results
Cons PAT zooms 73% YoY to Rs 562 crore, revenue rises 28%. Read More
Q3 Results Today Live Updates | ZEE Q3 results: PAT soars 180% YoY to Rs 164 crore
ZEE Entertainment Enterprises (ZEEL) on Thursday reported 180% year-on-year (YoY) growth in its consolidated net profit at Rs 164 crore in the third quarter, while operating revenue declined 3% YoY to Rs 1,979 crore. Read More
Q3 Results Today Live Updates | Adani Energy Q3 Results
Revenue at Rs 5830 cr vs Rs 4563 cr, up 27.8% YoY
PAT at Rs 625 cr vs Rs 348 cr, up 79.6% YoY
PAT at Rs 625 cr vs Rs 348 cr, up 79.6% YoY
UltraTech Cement Q3 Results Live Updates: Capacity expansion program
As part of its ongoing capacity expansion program, UltraTech commissioned an additional 1.8 mtpa capacity. With the acquisition of India Cements, the company’s cement capacity on a consolidated basis has increased to 171.11 mtpa.
Upon completing the ongoing expansion projects and the acquisition of Kesoram Cement (10.75 MTPA), UltraTech is set to achieve a milestone of over 200 mtpa cement capacity in India by the end of FY27.
Upon completing the ongoing expansion projects and the acquisition of Kesoram Cement (10.75 MTPA), UltraTech is set to achieve a milestone of over 200 mtpa cement capacity in India by the end of FY27.
UltraTech Cement Q3 Results Live Updates: Key financial highlights
Here's a snapshot of UltraTech Cement's Q3 numbers.
UltraTech Cement Q3 Results Live Updates: PAT falls 17% YoY to Rs 1,469 crore but beats estimates
Ultratech Cement reported a 17% year-on-year (YoY) decline in net profit, which stood at Rs 1,469.50 crore (attributable to shareholders), while revenue from operations grew by a marginal 3% YoY to Rs 17,193 crore.
The Street had estimated a profit of Rs 1,195 crore.
The Street had estimated a profit of Rs 1,195 crore.
UltraTech Cement Q3 Results: Key highlights
- Domestic sales volume grew 10.5% yoy and 9% qoq
- Trade volume grew 12.5% yoy and rural sales volume grew 13% you
- Domestic operating EBITDA/Mt of ₹ 964, higher by ₹ 232/Mt qoq
- The India Cements Limited (ICEM) has become a subsidiary of the Company with effect from 24th Dec, 2024.
- ICEM’s grey cement capacity is 14.45 mtpa.
- Green Power Mix of 33.4%, an improvement of 39% yoy, includes WHRS power mix of 19.9% and RE Power Mix of 13.5%.
UltraTech Cement Q3 Results Live Updates: UltraTech Cement share price rises 4% post Q3 earnings announcement
Share price rises over 4% to Rs 11,123.
Price as on 02.07.16 PM, Click on company names for their live prices.
UltraTech Cement Q3 Results: PAT at Rs 1,473 cr vs Street estimates of Rs 1,195 cr
Cons Revenue: Rs 17,193 cr vs Street estimates of Rs 16,854 cr.
Cons EBITDA: Rs 2,887 cr vs Street estimates of Rs 2,676 cr.
Cons Margin: 16.7% vs Street estimates of 15.9%.
Cons EBITDA: Rs 2,887 cr vs Street estimates of Rs 2,676 cr.
Cons Margin: 16.7% vs Street estimates of 15.9%.
UltraTech Cement Q3 Results Live Updates: Earnings outlook by Motilal Oswal
Sales volume is expected to grow by 10% YoY, while blended realization is likely to decline by 8% YoY. RMC revenue is projected to increase 10% YoY, and white cement revenue is expected to rise by 1% YoY.
EBITDA per tonne is estimated at Rs 925, compared to Rs 1,191 in 3QFY24 and Rs 725 in 2QFY25. Variable costs per tonne are anticipated to decline by 5% YoY, while operating expenses per tonne are likely to drop by 4% YoY.
EBITDA per tonne is estimated at Rs 925, compared to Rs 1,191 in 3QFY24 and Rs 725 in 2QFY25. Variable costs per tonne are anticipated to decline by 5% YoY, while operating expenses per tonne are likely to drop by 4% YoY.
DRL Q3 Results Live Updates: Dr. Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stable
Pharma major Dr. Reddy's is expected to report double-digit growth in both its bottomline and topline, driven by stable sales in the US and growth in the organic business.
Net profit for the quarter is projected to rise 10% year-on-year (YoY), according to the average estimate of four brokerages, while revenues are likely to increase 13% YoY.
Net profit for the quarter is projected to rise 10% year-on-year (YoY), according to the average estimate of four brokerages, while revenues are likely to increase 13% YoY.
DRL Q3 Results Live Updates: Earnings outlook by Nuvama
We expect Dr. Reddy’s revenue and EBITDA to grow by 17% and 13% YoY, respectively, with EBITDA margins reaching 27.5% for Q3FY25, supported by gRevlimid. We project US revenue at $427 million, driven by strong contributions from gRevlimid.
For the Indian business, we anticipate a 19% YoY growth, with an 11% YoY organic growth and a Rs 90 crore contribution from the vaccine business. We also expect improvement in China and Brazil, leading to growth in the Rest of the World (RoW) markets, as well as growth in Russia.
For the Indian business, we anticipate a 19% YoY growth, with an 11% YoY organic growth and a Rs 90 crore contribution from the vaccine business. We also expect improvement in China and Brazil, leading to growth in the Rest of the World (RoW) markets, as well as growth in Russia.
DRL Q3 Results Live Updates: Earnings preview by Kotak Equities
We anticipate a 4% QoQ decline in North America base business (excluding Revlimid) sales to $303 million, driven by market share losses in several molecules. Our estimates include $145 million in gRevlimid sales in the US for 3QFY25 for DRRD, up from $130 million in 2QFY25.
For DRRD’s domestic sales, we expect a 14% YoY growth in 2QFY25, supported by an 8% YoY growth in its organic business, along with contributions from in-licensing agreements with Sanofi and Bayer.
For DRRD’s domestic sales, we expect a 14% YoY growth in 2QFY25, supported by an 8% YoY growth in its organic business, along with contributions from in-licensing agreements with Sanofi and Bayer.
DRL Q3 Results Live Updates: Earnings preview by Centrum
US sales are expected to grow 7% YoY (CC) to $430 million, mainly due to muted growth in Lenalidomide. DF sales are projected to increase 15% YoY to Rs 1,400 crore, driven by the integration of the Sanofi portfolio.
Q3 Results Today Live Updates: Eye On Earnings
Here are top companies that will announce Q3 results today.
UltraTech Cement Q3 Results Live Updates: UltraTech shares gain 2% ahead of Q3 show
Shares of the company rose 1.69% to Rs 10,873 ahead of Q3 earnings announcement
Price as on 11.18.23 AM, Click on company names for their live prices.
DRL Q3 Results Live Updates: Dr Reddy’s Laboratories share price drops 1% ahead of Q3 show, following a downgrade to “underperform.”
Dr Reddy’s slipped to Rs 1282.40 after CLSA expressed concerns over generic price erosion and competition for key drugs, reducing its target price to Rs 1,090 from Rs 1,140, indicating a downside of around 15% from its current levels.
Price as on 10.49.00 AM, Click on company names for their live prices.
Adani Green Energy Q3 Results Live Updates: EPS Forecast
EPS is expected to grow by 134.0% in FY25.
Adani Green Energy Q3 Results Live Updates: Share price analysis
Here's how the company's stock has fared in the last 6 months, 1 year and three years.
Adani Green Energy Q3 Results Live Updates: Company's Q2 summary
Adani Green Energy reported a 39% jump in its consolidated net profit for the quarter ended September 2024 to Rs 515 crore as against Rs 371 crore posted in the year-ago period.
The revenue from operations for the reported quarter stood at Rs 3,376 crore, up 30% over Rs 2,589 crore posted by the company in the corresponding quarter of the previous financial year.
Adani Green Energy's H1FY25 EBITDA stood at Rs 4,518 crore and was up by 20% YoY.
The revenue from operations for the reported quarter stood at Rs 3,376 crore, up 30% over Rs 2,589 crore posted by the company in the corresponding quarter of the previous financial year.
Adani Green Energy's H1FY25 EBITDA stood at Rs 4,518 crore and was up by 20% YoY.
Adani Green Energy Q3 Results Live Updates: Share price analysis
Adani Green Energy has worse 1 year returns than Nifty50, industry, Sensex and sector.
Adani Green Energy Q3 Results Live Updates: Revenue Forecast
Adani Green Energy Ltd.'s revenue was higher than average estimate 2 times in past 2 years
Adani Green Energy Q3 Results Live Updates: Consensus recommendation
The consensus recommendation from 4 analysts for Adani Green Energy Ltd. is BUY.
DRL Q3 Results Live Updates: Analyst View
DRL Q3 Results 2025 Live: Analysts estimate US sales to be stable YoY at $405-427 million, led by limited volume offtake in the differentiated portfolio.
Key factors to watch out for include update on the potential approval in the US over the next 12-18 million, denosumab launch in EU, effect of licenses and partnerships formed in recent years.
Key factors to watch out for include update on the potential approval in the US over the next 12-18 million, denosumab launch in EU, effect of licenses and partnerships formed in recent years.
DRL Q3 Results Live Updates: Dr Reddy's Q3 expectations
DRL Q3 Results 2025 Live: Pharma major Dr. Reddy's is projected to report double-digit growth in both its bottomline and topline, driven by steady sales in the US and growth in its organic business.
Ultratech Cement Q3 Results Live Updates: Analyst View
Ultratech Cement Q3 Results 2025 Live: Ultratech is seeing pricing pressure from peer group despite having strong branding and market presence. Analysts also expect lower realizations during the quarter mainly on account of weak realization in white cement and clinker sale.
Ultratech Cement Q3 Results Live Updates: Ultratech Cement Q3 expectations
Ultratech Cement Q3 Results 2025 Live: Cement giant Ultratech is expected to report a decline in profitability for the quarter ending December 2024, although its topline is likely to see a slight increase.
Q3 Results Live Updates: Other important results today
Q3 Results 2025 Live: Companies like ZEE, Cyient, Greaves Cotton, IEX, LKP Securities, Mphasis, Nippon Life AMC, Senores Pharma, Sona BLW Precision and a few others will also declare their quarter results.
Q3 Results Live Updates: Q3 results today: Ultratech, Adani Green among 59 companies to announce earnings on Thursday
Q3 Results 2025 Live: The third quarter earnings season is underway and about 59 companies will announce their results on Thursday. Key results to watch out for include Ultratech Cement, Adani Green, Dr Reddy's, Mankind Pharma and HPCL.
